Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Br J Cancer. 2023 Mar;128(7):1177-1188. doi: 10.1038/s41416-022-02110-z. Epub 2022 Dec 26.
Sequential multiple assignments randomized trials (SMARTs) are a type of experimental design where patients may be randomised multiple times according to pre-specified decision rules. The present work investigates the state-of-the-art of SMART designs in oncology, focusing on the discrepancy between the available methodological approaches in the statistical literature and the procedures applied within cancer clinical trials. A systematic review was conducted, searching PubMed, Embase and CENTRAL for protocols or reports of results of SMART designs and registrations of SMART designs in clinical trial registries applied to solid tumour research. After title/abstract and full-text screening, 33 records were included. Fifteen were reports of trials' results, four were trials' protocols and fourteen were trials' registrations. The study design was defined as SMART by only one out of fifteen trial reports. Conversely, 13 of 18 study protocols and trial registrations defined the study design SMART. Furthermore, most of the records considered each stage separately in the analysis, without considering treatment regimens embedded in the trial. SMART designs in oncology are still limited. Study powering and analysis is mainly based on statistical approaches traditionally used in single-stage parallel trial designs. Formal reporting guidelines for SMART designs are needed.
序贯多次分配随机试验 (SMARTs) 是一种实验设计,其中患者可能根据预先指定的决策规则多次被随机分配。本研究调查了肿瘤学中 SMART 设计的最新进展,重点关注统计文献中可用的方法学方法与癌症临床试验中应用的程序之间的差异。我们进行了系统评价,在 PubMed、Embase 和 CENTRAL 中搜索了 SMART 设计的方案或结果报告以及应用于实体瘤研究的临床试验注册中的 SMART 设计的注册。经过标题/摘要和全文筛选,共纳入 33 份记录。其中 15 份是试验结果的报告,4 份是试验方案,14 份是试验注册。只有 15 份试验报告中的 1 份将研究设计定义为 SMART。相反,18 项研究方案和试验注册中有 13 项将研究设计定义为 SMART。此外,大多数记录在分析中分别考虑了每个阶段,而没有考虑试验中嵌入的治疗方案。肿瘤学中的 SMART 设计仍然有限。研究动力和分析主要基于传统上用于单阶段平行试验设计的统计方法。需要制定 SMART 设计的正式报告指南。